Current Progress of Phytomedicine in Glioblastoma Therapy
- PMID: 33428134
- DOI: 10.1007/s11596-020-2288-8
Current Progress of Phytomedicine in Glioblastoma Therapy
Abstract
Glioblastoma multiforme, an intrusive brain cancer, has the lowest survival rate of all brain cancers. The chemotherapy utilized to prevent their proliferation and propagation is limited due to modulation of complex cancer signalling pathways. These complex pathways provide infiltrative and drug evading properties leading to the development of chemotherapy resistance. Therefore, the development and discovery of such interventions or therapies that can bypass all these resistive barriers to ameliorate glioma prognosis and survival is of profound importance. Medicinal plants are comprised of an exorbitant range of phytochemicals that have the broad-spectrum capability to target intrusive brain cancers, modulate anti-cancer pathways and immunological responses to facilitate their eradication, and induce apoptosis. These phytocompounds also interfere with several oncogenic proteins that promote cancer invasiveness and metastasis, chemotherapy resistance and angiogenesis. These plants are extremely vital for promising anti-glioma therapy to avert glioma proliferation and recurrence. In this review, we acquired recent literature on medicinal plants whose extracts/bioactive ingredients are newly exploited in glioma therapeutics, and also highlighted their mode of action and pharmacological profile.
Keywords: bioactive; chemotherapy resistance; glioblastoma; phytochemicals; phytomedicine.
Similar articles
-
Medicinal Plants for Glioblastoma Treatment.Anticancer Agents Med Chem. 2022;22(13):2367-2384. doi: 10.2174/1871520622666211221144739. Anticancer Agents Med Chem. 2022. PMID: 34939551 Review.
-
Phytochemical strategies in glioblastoma therapy: Mechanisms, efficacy, and future perspectives.Biochim Biophys Acta Mol Basis Dis. 2025 Mar;1871(3):167647. doi: 10.1016/j.bbadis.2024.167647. Epub 2024 Dec 30. Biochim Biophys Acta Mol Basis Dis. 2025. PMID: 39740382 Review.
-
Natural bioactive molecules: An alternative approach to the treatment and control of glioblastoma multiforme.Biomed Pharmacother. 2021 Sep;141:111928. doi: 10.1016/j.biopha.2021.111928. Epub 2021 Jul 19. Biomed Pharmacother. 2021. PMID: 34323701 Review.
-
Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors.J Neurochem. 2007 Jul;102(2):522-38. doi: 10.1111/j.1471-4159.2007.04633.x. J Neurochem. 2007. PMID: 17596214
-
Microenvironment-Derived Regulation of HIF Signaling Drives Transcriptional Heterogeneity in Glioblastoma Multiforme.Mol Cancer Res. 2018 Apr;16(4):655-668. doi: 10.1158/1541-7786.MCR-17-0680. Epub 2018 Jan 12. Mol Cancer Res. 2018. PMID: 29330292
Cited by
-
Evaluation of phytochemicals of Poria cocos against tyrosinase protein: a virtual screening, pharmacoinformatics and molecular dynamics study.3 Biotech. 2023 Jun;13(6):199. doi: 10.1007/s13205-023-03626-8. Epub 2023 May 18. 3 Biotech. 2023. PMID: 37215373 Free PMC article.
-
SLNP-based CDK4- targeted nanotherapy against glioblastoma.Front Oncol. 2024 Nov 22;14:1455816. doi: 10.3389/fonc.2024.1455816. eCollection 2024. Front Oncol. 2024. PMID: 39650055 Free PMC article.
-
Improve BBB Penetration and Cytotoxicity of Palbociclib in U87-MG Glioblastoma Cells Delivered by Dual Peptide Functionalized Nanoparticles.Pharmaceutics. 2023 Oct 6;15(10):2429. doi: 10.3390/pharmaceutics15102429. Pharmaceutics. 2023. PMID: 37896189 Free PMC article.
-
Uncovering naringin's anticancer mechanisms in glioblastoma via molecular docking and network pharmacology approaches.Sci Rep. 2024 Sep 14;14(1):21486. doi: 10.1038/s41598-024-72475-z. Sci Rep. 2024. PMID: 39277626 Free PMC article.
-
SapC-DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents.Pharmaceuticals (Basel). 2021 Nov 20;14(11):1193. doi: 10.3390/ph14111193. Pharmaceuticals (Basel). 2021. PMID: 34832975 Free PMC article. Review.
References
-
- Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther, 2015,152:63–82 - PubMed
-
- Crespo I, Vital AL, Gonzalez-Tablas M, et al. Molecular and Genomic Alterations in Glioblastoma Multiforme. Am J Pathol, 2015,185(7): 1820–1833 - PubMed
-
- Anjum K, Shagufta BI, Abbas SQ, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review. Biomed Pharmacother, 2017,92:681–689 - PubMed
-
- Stavrovskaya AA, Shushanov SS, Rybalkina EY. Problems of glioblastoma multiforme drug resistance. Biochem, 2016,81(2):91–100
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical